| Website | ptcbio.com |
| @PTCTherapeutics | |
| Category | BioTech |
| Phone | 908-222-7000 |
| info@ptcbio.com | |
| Employees | |
| Founded | 1998 |
| TOTAL | $173M |
| FUNDING TOTAL | $173M |
| Venture Round, 11/05 CSFB Private Equity HBM BioVentures Vulcan Capital Novo A/S Delphi Ventures Bay City Capital Novartis Bioventures Amgen Ventures HealthCap | $26.6M |
| Grant, 12/09 | $1M |
| Series E, 12/09 Delphi Ventures Credit Suisse HBM BioVentures Novo A/S The Column Group | $50M |
| Venture Round, 12/11 Wellcome Trust | $5M |
| Venture Round, 7/12 Credit Suisse First Boston Next Fund HBM BioVentures Delphi Ventures Novo A/S | $30M |
| Venture Round, 3/13 Brookside Capital Adage Capital Management Jennison Associates Longwood Founders Fund Credit Suisse First Boston Next Fund Vulcan Capital Delphi Ventures Novo A/S | $60M |
PTC Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of orally administered and small-molecule drugs. It offers Ataluren, an orally administered small-molecule investigational new drug for the treatment of cystic fibrosis and duchenne muscular dystrophy caused by nonsense mutations. The company also provides PTC299, an anti-angiogenesis drug for the treatment of metastatic breast cancer, multiple tumors, and neurofibromatosis. Its products are used for the treatment of genetic disorders, oncology, and infectious diseases. PTC Therapeutics, Inc. was founded in 1998 and is based in South Plainfield, New Jersey.
